Latest issue of Clinical laboratory
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
MIMETAS unveils breakthrough in flow system technology for disease modelling
, /in Product News /by panglobalMIMETAS has introduced OrganoPlate UniFlow (UF), the first commercial platform offering unidirectional, gravity-driven pumpless flow systems for disease research. This innovation significantly advances tissue model development for pharmaceutical research by replicating physiological conditions without complex equipment.
CN Bio releases new in vitro DILI assay kit for toxicology screening
, /in Product News /by panglobalCN Bio has launched an all-in-one drug-induced liver injury (DILI) testing kit that enables pharmaceutical researchers to conduct in-house hepatotoxicity screening using organ-on-chip technology. The system provides human-relevant data to support more informed candidate selection during preclinical development.
Edx Medical pioneers multi-biomarker testing approach for prostate cancer detection
, /in Product News /by panglobalCambridge scientists at EDX Medical Group have developed an innovative diagnostic test for prostate cancer that combines over 100 biomarkers with AI analysis, potentially transforming screening accuracy with sensitivity and specificity rates between 96-99%.
AI-powered virtual cell platform expands as Shift Bioscience establishes Toronto base
, /in E-News /by panglobalThe Cambridge-based biotech company Shift Bioscience has announced the establishment of new facilities in Toronto, Canada, marking a strategic expansion of their AI capabilities in the development of virtual cell technology. The move follows their recent $16M seed funding round and positions the company to tap into North America’s rich pool of artificial intelligence talent.
Artificial integrates NVIDIA’s BioNeMo to advance AI-driven drug discovery workflows
, /in E-News /by panglobalArtificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.
Sapio Sciences bolsters leadership team to accelerate AI-driven lab informatics evolution
, /in E-News /by panglobalSapio Sciences has announced significant leadership changes designed to strengthen its position in the AI-driven lab informatics sector. The Baltimore-based company, known for its “science-aware” platform, has appointed Mike Hampton as Chief Commercial Officer while simultaneously establishing a dedicated Scientific Office to enhance its research and development capabilities.
Ten-minute cardiac diagnostics: bioMérieux’s strategic acquisition targets emergency care transformation
, /in E-News /by panglobalbioMérieux has announced the acquisition of SpinChip Diagnostics ASA, a privately held Norwegian company specialising in rapid immunoassay diagnostics. The €138 million deal will see bioMérieux acquire 100% ownership of the company, with a cash outlay of approximately €111 million, accounting for the 20% minority stake bioMérieux has held since March 2024.
Nuclera enhances its leadership team with the appointment of William J. Kullback as non-executive director
, /in E-News /by panglobalNuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.
Glox Therapeutics invigorates leadership team to advance bacteriocin-based antibiotics
, /in E-News /by panglobalGlox Therapeutics has announced strategic appointments to accelerate the development of its novel bacteriocin-based antibiotic platform, with Dr Michael Murray joining as Chair and Dr Nel Moore strengthening the Scientific Advisory Board. The Glasgow-based biotechnology company is pioneering a distinctive approach to combating antimicrobial resistance (AMR) through engineered protein bacteriocins that selectively target drug-resistant pathogens.
Eleva strengthens clinical leadership with appointment of Martin Bauer as CMO
, /in E-News /by panglobalEleva, the Freiburg-based biopharmaceutical company specialising in difficult-to-produce biologics via its proprietary moss-based expression system, has announced a significant addition to its leadership team as it prepares to enter a crucial clinical development phase.